- PR Newswire•2 months ago
WARSAW, Ind., Dec. 13, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of PrimaGen Advanced Allograft, an autograft substitute containing the same bone healing elements as autograft, but without the risks associated with donor site morbidity or harvest site complications. Allograft is human tissue transplanted from a donor to a patient, while autograft tissue is transferred from one part of a patient's body to another. PrimaGen Advanced Allograft offers a combination of demineralized cortical bone fibers with verified osteoinductivity and cancellous bone, providing a trabecular structure for natural bony in-growth with optimal handling and delivery characteristics. Dr. Donald Kucharzyk*, Orthopaedic Surgeon at The Orthopaedic, Pediatric and Spine Institute in Crown Point, Ind., was one of the first surgeons to use PrimaGen Advanced Allograft. "The syringe allows for easy preparation and replication of the graft consistency prior to each use," noted Dr. Kucharzyk, who was pleased with the new delivery system, as well as the handling, moldability and stability under irrigation.
- Market Realist•2 months ago
Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion for 3Q16 compared to 3Q15.
- Reuters•3 months ago
U.S. authorities will reach a settlement with medical device maker Zimmer Biomet Holdings Inc over bribery allegations in the next four weeks, prosecutors said in a court filing Thursday. The new agreement would replace a 2012 settlement with the U.S. Justice Department over allegations that Biomet paid bribes to state-employed healthcare providers in Argentina, Brazil and China in order to win business. Prosecutors said in June that Biomet breached that agreement after the company came forward with new allegations of misconduct in Mexico and Brazil.
ZMH : Summary for Zimmer Holdings, Inc. Common St - Yahoo Finance